(DCPH) – Trader Talk
-
Deciphera (DCPH) Climbs 125% After Phase 3 Clinical Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors Achieves Primary Endpoint
-
Options expected to have increasing volume: DCPH ODT GTHX PBYI IMMU AMGN PBR DB
Back to DCPH Stock Lookup